Bannerbild German Brest Group

Paper of the month: Endocrine Therapy in HEGR2 neg mBC

31.08.2018

A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.

During the past 30 years, the incidence of metastatic breast cancer (MBC) in women aged 25-39 years has slightly increased. Up to date, no comprehensive review exists for therapeutic approaches in that patient population. Therefore, this review aimed to provide clinicians with an overview on the available data regarding endocrine treatment of hormone receptor-positive MBC in premenopausal women and to indicate potential future directions of research.

Tancredi R, Furlanetto J, Loibl S. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. Oncologist. 2018; 23:974-981.

Link in PubMed

The Oncologist

News

  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

    Mehr ...
  • 15.11.2018 Save the Date: AGO-Mamma 2019

    Save the Date: AGO-Mamma 2019

    Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.

    Mehr ...
  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd